| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Keratitis | 50 | 2010 | 102 | 5.870 |
Why?
|
| Eye Infections, Fungal | 28 | 2010 | 71 | 5.450 |
Why?
|
| Corneal Ulcer | 25 | 2010 | 49 | 4.910 |
Why?
|
| Keratitis, Herpetic | 18 | 2020 | 28 | 4.570 |
Why?
|
| Cornea | 55 | 2015 | 638 | 4.070 |
Why?
|
| Eye Infections, Bacterial | 25 | 2007 | 96 | 3.790 |
Why?
|
| Candidiasis | 18 | 2010 | 262 | 3.070 |
Why?
|
| Corneal Stroma | 17 | 2020 | 80 | 2.040 |
Why?
|
| Candida albicans | 15 | 2010 | 175 | 2.010 |
Why?
|
| Debridement | 10 | 2015 | 123 | 1.970 |
Why?
|
| Antiviral Agents | 19 | 2020 | 1230 | 1.790 |
Why?
|
| Fungal Proteins | 7 | 2010 | 254 | 1.720 |
Why?
|
| Corneal Diseases | 13 | 2015 | 89 | 1.600 |
Why?
|
| Endophthalmitis | 12 | 2008 | 84 | 1.380 |
Why?
|
| Eye Infections, Viral | 4 | 2020 | 30 | 1.380 |
Why?
|
| Acanthamoeba Keratitis | 8 | 2008 | 16 | 1.320 |
Why?
|
| Tissue Donors | 13 | 2011 | 769 | 1.200 |
Why?
|
| Prednisolone | 10 | 2020 | 123 | 1.170 |
Why?
|
| Eye Banks | 9 | 2011 | 12 | 1.140 |
Why?
|
| Bacteria | 13 | 2007 | 611 | 1.070 |
Why?
|
| Fungi | 9 | 2007 | 145 | 1.060 |
Why?
|
| Glucocorticoids | 6 | 2020 | 629 | 0.980 |
Why?
|
| Probability | 5 | 2011 | 866 | 0.960 |
Why?
|
| Keratitis, Dendritic | 14 | 2000 | 18 | 0.950 |
Why?
|
| Administration, Topical | 21 | 2015 | 257 | 0.950 |
Why?
|
| Fusarium | 3 | 2010 | 50 | 0.930 |
Why?
|
| Keratoplasty, Penetrating | 15 | 2011 | 48 | 0.920 |
Why?
|
| Corneal Transplantation | 12 | 2007 | 39 | 0.900 |
Why?
|
| Mycoses | 9 | 2010 | 386 | 0.860 |
Why?
|
| Acyclovir | 15 | 2009 | 78 | 0.800 |
Why?
|
| Hyphae | 4 | 2010 | 44 | 0.800 |
Why?
|
| Gene Expression Regulation, Fungal | 3 | 2010 | 108 | 0.750 |
Why?
|
| Organ Preservation | 6 | 2011 | 43 | 0.710 |
Why?
|
| Contact Lenses | 8 | 2008 | 45 | 0.710 |
Why?
|
| Mice, Inbred BALB C | 15 | 2010 | 2314 | 0.700 |
Why?
|
| Endothelium, Corneal | 5 | 2011 | 33 | 0.670 |
Why?
|
| Data Interpretation, Statistical | 3 | 2004 | 482 | 0.630 |
Why?
|
| Disinfectants | 2 | 2015 | 35 | 0.620 |
Why?
|
| Contact Lens Solutions | 2 | 2015 | 7 | 0.600 |
Why?
|
| Ophthalmic Solutions | 13 | 2020 | 101 | 0.580 |
Why?
|
| Climate | 2 | 2006 | 23 | 0.570 |
Why?
|
| Ciprofloxacin | 3 | 2003 | 89 | 0.570 |
Why?
|
| Gene Expression Regulation | 5 | 2010 | 4053 | 0.560 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2015 | 14 | 0.550 |
Why?
|
| Lubricant Eye Drops | 1 | 2015 | 11 | 0.550 |
Why?
|
| Graft Rejection | 6 | 2011 | 834 | 0.530 |
Why?
|
| Antiprotozoal Agents | 6 | 2008 | 40 | 0.530 |
Why?
|
| Bacterial Infections | 11 | 2007 | 479 | 0.490 |
Why?
|
| Polymers | 1 | 2015 | 223 | 0.490 |
Why?
|
| Visual Acuity | 16 | 2020 | 873 | 0.480 |
Why?
|
| Fluoroquinolones | 3 | 2004 | 126 | 0.480 |
Why?
|
| Humans | 157 | 2020 | 261506 | 0.470 |
Why?
|
| Trifluridine | 8 | 2020 | 30 | 0.470 |
Why?
|
| Conjunctiva | 7 | 2003 | 250 | 0.470 |
Why?
|
| Sclera | 5 | 2007 | 69 | 0.470 |
Why?
|
| Virulence | 7 | 2010 | 323 | 0.460 |
Why?
|
| Ascomycota | 2 | 2005 | 31 | 0.460 |
Why?
|
| Acanthamoeba | 5 | 2007 | 17 | 0.450 |
Why?
|
| Drug Therapy, Combination | 10 | 2011 | 2315 | 0.450 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2010 | 3639 | 0.450 |
Why?
|
| Eye Infections, Parasitic | 2 | 2007 | 7 | 0.440 |
Why?
|
| Herpes Simplex | 1 | 2013 | 95 | 0.440 |
Why?
|
| Iris | 2 | 2008 | 67 | 0.420 |
Why?
|
| Photomicrography | 2 | 2011 | 26 | 0.420 |
Why?
|
| Disease Models, Animal | 12 | 2010 | 7222 | 0.420 |
Why?
|
| Corneal Neovascularization | 3 | 2009 | 14 | 0.400 |
Why?
|
| Corneal Edema | 3 | 2004 | 12 | 0.400 |
Why?
|
| Ultraviolet Rays | 1 | 2013 | 575 | 0.400 |
Why?
|
| Administration, Oral | 11 | 2015 | 1544 | 0.390 |
Why?
|
| Anti-Infective Agents | 4 | 2003 | 446 | 0.390 |
Why?
|
| beta-Defensins | 1 | 2010 | 30 | 0.380 |
Why?
|
| Cataract Extraction | 7 | 2008 | 184 | 0.380 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 1997 | 158 | 0.380 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2010 | 62 | 0.370 |
Why?
|
| Chemokines, CC | 1 | 2009 | 36 | 0.360 |
Why?
|
| Confidence Intervals | 4 | 2008 | 756 | 0.360 |
Why?
|
| Aspergillus nidulans | 1 | 2009 | 28 | 0.360 |
Why?
|
| Female | 84 | 2020 | 141928 | 0.360 |
Why?
|
| Culture Media | 4 | 2006 | 319 | 0.360 |
Why?
|
| Corneal Injuries | 3 | 2007 | 29 | 0.360 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 4 | 2010 | 189 | 0.350 |
Why?
|
| Chemokines, CXC | 1 | 2009 | 117 | 0.350 |
Why?
|
| Proteoglycans | 1 | 2010 | 259 | 0.350 |
Why?
|
| Eye Injuries | 3 | 2007 | 57 | 0.340 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 3 | 2004 | 104 | 0.340 |
Why?
|
| Microbial Sensitivity Tests | 8 | 2009 | 994 | 0.340 |
Why?
|
| Syphilis | 2 | 2006 | 61 | 0.340 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2010 | 2508 | 0.340 |
Why?
|
| Eyelid Diseases | 2 | 2006 | 76 | 0.340 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 174 | 0.330 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2010 | 315 | 0.330 |
Why?
|
| Male | 80 | 2020 | 123000 | 0.330 |
Why?
|
| Gene Expression Profiling | 6 | 2009 | 5159 | 0.330 |
Why?
|
| Cysteine Endopeptidases | 1 | 2009 | 251 | 0.320 |
Why?
|
| Vitreous Body | 3 | 2003 | 123 | 0.320 |
Why?
|
| Models, Statistical | 2 | 2004 | 1171 | 0.320 |
Why?
|
| Parasitology | 2 | 1998 | 9 | 0.320 |
Why?
|
| Matrix Metalloproteinases | 1 | 2009 | 143 | 0.320 |
Why?
|
| Animals | 41 | 2010 | 59536 | 0.320 |
Why?
|
| Middle Aged | 60 | 2020 | 86204 | 0.310 |
Why?
|
| Cataract | 2 | 2008 | 218 | 0.310 |
Why?
|
| Adult | 55 | 2020 | 77950 | 0.310 |
Why?
|
| Research | 2 | 2001 | 415 | 0.310 |
Why?
|
| Ophthalmology | 4 | 2004 | 198 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2015 | 2594 | 0.300 |
Why?
|
| Aspergillosis | 1 | 2009 | 246 | 0.300 |
Why?
|
| Seasons | 3 | 2005 | 340 | 0.290 |
Why?
|
| Orbital Diseases | 3 | 2006 | 118 | 0.290 |
Why?
|
| Signal Transduction | 3 | 2010 | 11965 | 0.290 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2002 | 461 | 0.290 |
Why?
|
| Organ Preservation Solutions | 2 | 2011 | 20 | 0.290 |
Why?
|
| Amebiasis | 3 | 1994 | 15 | 0.290 |
Why?
|
| Necrobiotic Disorders | 1 | 2006 | 3 | 0.290 |
Why?
|
| Functional Laterality | 1 | 2008 | 316 | 0.280 |
Why?
|
| Scleritis | 1 | 2006 | 13 | 0.280 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 256 | 0.280 |
Why?
|
| Xanthomatosis | 1 | 2006 | 21 | 0.280 |
Why?
|
| Genes, Fungal | 4 | 2010 | 84 | 0.280 |
Why?
|
| Opportunistic Infections | 2 | 2006 | 223 | 0.280 |
Why?
|
| Transcription Factors | 2 | 2010 | 5270 | 0.270 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 360 | 0.270 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 703 | 0.270 |
Why?
|
| Conjunctivitis | 6 | 2015 | 31 | 0.270 |
Why?
|
| Keratoconjunctivitis | 3 | 2001 | 21 | 0.270 |
Why?
|
| Publishing | 3 | 2007 | 220 | 0.270 |
Why?
|
| Temperature | 2 | 2005 | 506 | 0.260 |
Why?
|
| Strabismus | 2 | 2004 | 213 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 12 | 2009 | 2992 | 0.260 |
Why?
|
| DNA-Binding Proteins | 2 | 2010 | 4821 | 0.260 |
Why?
|
| Lateral Medullary Syndrome | 1 | 2004 | 2 | 0.260 |
Why?
|
| Vision, Low | 1 | 2004 | 18 | 0.260 |
Why?
|
| Periodicals as Topic | 2 | 2007 | 338 | 0.250 |
Why?
|
| Granuloma | 1 | 2006 | 154 | 0.250 |
Why?
|
| Iridocyclitis | 2 | 1996 | 3 | 0.250 |
Why?
|
| Drug Contamination | 2 | 2000 | 52 | 0.250 |
Why?
|
| Mice | 16 | 2010 | 34495 | 0.240 |
Why?
|
| Aged | 49 | 2015 | 70117 | 0.240 |
Why?
|
| Mycobacterium chelonae | 1 | 2003 | 6 | 0.240 |
Why?
|
| Interferons | 3 | 2015 | 291 | 0.240 |
Why?
|
| Head Movements | 1 | 2004 | 31 | 0.240 |
Why?
|
| Prospective Studies | 17 | 2011 | 12873 | 0.240 |
Why?
|
| Nystagmus, Pathologic | 1 | 2004 | 43 | 0.240 |
Why?
|
| Benzamidines | 3 | 2008 | 12 | 0.230 |
Why?
|
| Recurrence | 12 | 2013 | 4758 | 0.230 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1996 | 362 | 0.220 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2003 | 82 | 0.220 |
Why?
|
| Microbiological Techniques | 3 | 2003 | 40 | 0.220 |
Why?
|
| Posture | 1 | 2004 | 215 | 0.220 |
Why?
|
| Risk Factors | 17 | 2008 | 17523 | 0.210 |
Why?
|
| Syphilis, Congenital | 1 | 2002 | 25 | 0.210 |
Why?
|
| Postoperative Complications | 7 | 2008 | 5542 | 0.210 |
Why?
|
| Head | 1 | 2004 | 249 | 0.210 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2009 | 585 | 0.210 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 1648 | 0.210 |
Why?
|
| Sex Characteristics | 1 | 2004 | 417 | 0.200 |
Why?
|
| Combined Modality Therapy | 7 | 2015 | 8865 | 0.200 |
Why?
|
| Chlorhexidine | 3 | 2008 | 88 | 0.200 |
Why?
|
| Pseudomonas Infections | 4 | 1995 | 156 | 0.200 |
Why?
|
| Irritants | 1 | 2001 | 6 | 0.200 |
Why?
|
| Amoeba | 2 | 1999 | 5 | 0.200 |
Why?
|
| Journalism, Medical | 1 | 2001 | 11 | 0.200 |
Why?
|
| Myopia | 3 | 2010 | 194 | 0.200 |
Why?
|
| Adolescent | 29 | 2015 | 31252 | 0.200 |
Why?
|
| Capnocytophaga | 2 | 1994 | 4 | 0.200 |
Why?
|
| Toxicity Tests | 1 | 2001 | 50 | 0.200 |
Why?
|
| Retrospective Studies | 21 | 2011 | 37905 | 0.200 |
Why?
|
| Publications | 1 | 2001 | 54 | 0.190 |
Why?
|
| Xanthenes | 1 | 2000 | 8 | 0.190 |
Why?
|
| Colorimetry | 1 | 2000 | 31 | 0.190 |
Why?
|
| Administration, Ophthalmic | 1 | 2020 | 5 | 0.190 |
Why?
|
| Oxazines | 1 | 2000 | 43 | 0.190 |
Why?
|
| Vibrio Infections | 1 | 2000 | 11 | 0.180 |
Why?
|
| Benzenesulfonates | 2 | 1994 | 195 | 0.180 |
Why?
|
| Vitrectomy | 3 | 2010 | 100 | 0.180 |
Why?
|
| Vibrio | 1 | 2000 | 6 | 0.180 |
Why?
|
| Contact Lenses, Hydrophilic | 4 | 2015 | 15 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 3 | 2003 | 3203 | 0.180 |
Why?
|
| Clinical Trials as Topic | 5 | 2007 | 3719 | 0.180 |
Why?
|
| Tissue and Organ Procurement | 3 | 2006 | 233 | 0.180 |
Why?
|
| Surgical Wound Infection | 1 | 2003 | 450 | 0.180 |
Why?
|
| Water Microbiology | 1 | 1999 | 22 | 0.180 |
Why?
|
| Antifungal Agents | 6 | 2007 | 834 | 0.180 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2001 | 503 | 0.180 |
Why?
|
| Double-Blind Method | 6 | 2020 | 2588 | 0.180 |
Why?
|
| Cysts | 3 | 1998 | 197 | 0.180 |
Why?
|
| Streptococcus pneumoniae | 3 | 1998 | 330 | 0.180 |
Why?
|
| Penicillin Resistance | 2 | 1998 | 69 | 0.180 |
Why?
|
| Repressor Proteins | 1 | 2007 | 1664 | 0.170 |
Why?
|
| Eye | 4 | 2003 | 301 | 0.170 |
Why?
|
| Aging | 2 | 2004 | 1582 | 0.170 |
Why?
|
| Pneumococcal Infections | 2 | 1998 | 241 | 0.160 |
Why?
|
| Cohort Studies | 7 | 2013 | 9244 | 0.160 |
Why?
|
| Keratoconus | 2 | 1998 | 53 | 0.160 |
Why?
|
| Colony Count, Microbial | 5 | 2007 | 149 | 0.160 |
Why?
|
| Quality Control | 3 | 2007 | 457 | 0.150 |
Why?
|
| Time Factors | 13 | 2011 | 12926 | 0.150 |
Why?
|
| Rabbits | 12 | 2000 | 957 | 0.150 |
Why?
|
| Gram-Negative Bacteria | 2 | 1997 | 100 | 0.150 |
Why?
|
| Water | 1 | 1999 | 361 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2004 | 806 | 0.150 |
Why?
|
| Xanthomonas | 1 | 1996 | 3 | 0.140 |
Why?
|
| Immunosuppressive Agents | 4 | 2007 | 1375 | 0.140 |
Why?
|
| Body Temperature | 2 | 2007 | 158 | 0.140 |
Why?
|
| Predictive Value of Tests | 4 | 2007 | 4892 | 0.140 |
Why?
|
| Follow-Up Studies | 12 | 2020 | 14889 | 0.140 |
Why?
|
| Antiparasitic Agents | 1 | 1996 | 39 | 0.140 |
Why?
|
| Swine | 2 | 2010 | 1541 | 0.130 |
Why?
|
| Hair | 1 | 1995 | 42 | 0.130 |
Why?
|
| Lipidoses | 1 | 1995 | 4 | 0.130 |
Why?
|
| Staining and Labeling | 2 | 1994 | 429 | 0.130 |
Why?
|
| Aged, 80 and over | 12 | 2015 | 29902 | 0.130 |
Why?
|
| Cyclophosphamide | 3 | 2007 | 3001 | 0.130 |
Why?
|
| Staphylococcal Infections | 4 | 1995 | 672 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 3 | 2010 | 6942 | 0.120 |
Why?
|
| Ganciclovir | 1 | 1995 | 174 | 0.120 |
Why?
|
| Body Weights and Measures | 2 | 2004 | 52 | 0.120 |
Why?
|
| Lens Nucleus, Crystalline | 1 | 2014 | 3 | 0.120 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 1995 | 67 | 0.120 |
Why?
|
| Capsulorhexis | 1 | 2014 | 12 | 0.120 |
Why?
|
| Viscosupplements | 1 | 2014 | 10 | 0.120 |
Why?
|
| Retinal Degeneration | 1 | 1995 | 85 | 0.120 |
Why?
|
| Glaucoma | 2 | 2008 | 92 | 0.120 |
Why?
|
| State Government | 1 | 1994 | 33 | 0.120 |
Why?
|
| Child | 19 | 2008 | 29154 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2001 | 2218 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 2 | 1996 | 462 | 0.120 |
Why?
|
| Sunlight | 1 | 2013 | 79 | 0.120 |
Why?
|
| Tobramycin | 3 | 1987 | 21 | 0.110 |
Why?
|
| Tacrolimus | 1 | 1995 | 335 | 0.110 |
Why?
|
| Trabeculectomy | 2 | 2008 | 15 | 0.110 |
Why?
|
| Up-Regulation | 2 | 2010 | 2450 | 0.110 |
Why?
|
| DNA, Fungal | 3 | 2003 | 127 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2010 | 6100 | 0.110 |
Why?
|
| Eye Diseases | 7 | 1987 | 132 | 0.110 |
Why?
|
| Biguanides | 2 | 2008 | 12 | 0.110 |
Why?
|
| Hyaluronic Acid | 1 | 2014 | 168 | 0.110 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2002 | 121 | 0.110 |
Why?
|
| Guanine | 3 | 1982 | 151 | 0.110 |
Why?
|
| Genotype | 2 | 2010 | 4109 | 0.100 |
Why?
|
| Ointments | 4 | 2003 | 27 | 0.100 |
Why?
|
| Corneal Opacity | 1 | 1991 | 23 | 0.100 |
Why?
|
| Treatment Outcome | 10 | 2020 | 32848 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2008 | 2316 | 0.100 |
Why?
|
| Chickenpox | 1 | 1991 | 31 | 0.100 |
Why?
|
| Amphotericin B | 3 | 2009 | 289 | 0.100 |
Why?
|
| Registries | 3 | 2008 | 2170 | 0.100 |
Why?
|
| Photography | 2 | 2009 | 139 | 0.100 |
Why?
|
| Cathelicidins | 1 | 2010 | 25 | 0.100 |
Why?
|
| Phacoemulsification | 1 | 2014 | 221 | 0.100 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1990 | 67 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2010 | 1062 | 0.090 |
Why?
|
| Refraction, Ocular | 2 | 2010 | 289 | 0.090 |
Why?
|
| Herpesviridae Infections | 2 | 2000 | 175 | 0.090 |
Why?
|
| Cryopreservation | 1 | 2011 | 175 | 0.090 |
Why?
|
| Immunocompetence | 1 | 2010 | 75 | 0.090 |
Why?
|
| Syphilis Serodiagnosis | 2 | 2006 | 10 | 0.090 |
Why?
|
| Metalloproteases | 1 | 2009 | 24 | 0.090 |
Why?
|
| Premedication | 3 | 2003 | 135 | 0.090 |
Why?
|
| Antibodies, Viral | 2 | 1987 | 1320 | 0.090 |
Why?
|
| Edema | 2 | 1989 | 267 | 0.090 |
Why?
|
| Retinopathy of Prematurity | 1 | 2010 | 88 | 0.090 |
Why?
|
| Retinal Detachment | 1 | 2010 | 88 | 0.090 |
Why?
|
| Genome, Fungal | 1 | 2009 | 54 | 0.090 |
Why?
|
| Paecilomyces | 1 | 2009 | 8 | 0.090 |
Why?
|
| Laser Coagulation | 1 | 2010 | 136 | 0.090 |
Why?
|
| Reoperation | 3 | 2011 | 1382 | 0.090 |
Why?
|
| Acridine Orange | 1 | 1988 | 10 | 0.090 |
Why?
|
| Adenoviridae Infections | 2 | 1987 | 125 | 0.090 |
Why?
|
| Phenazines | 1 | 1988 | 13 | 0.090 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2009 | 43 | 0.090 |
Why?
|
| Gentian Violet | 1 | 1988 | 20 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 1972 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2010 | 875 | 0.080 |
Why?
|
| Zinc Fingers | 1 | 2009 | 205 | 0.080 |
Why?
|
| Uveitis, Anterior | 3 | 1985 | 7 | 0.080 |
Why?
|
| Streptococcus | 1 | 1989 | 68 | 0.080 |
Why?
|
| Child, Preschool | 10 | 2010 | 16273 | 0.080 |
Why?
|
| Eye Infections | 1 | 2008 | 4 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 4971 | 0.080 |
Why?
|
| Dacryocystitis | 2 | 2000 | 25 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2009 | 4314 | 0.080 |
Why?
|
| Laser Therapy | 1 | 1992 | 411 | 0.080 |
Why?
|
| Models, Biological | 3 | 2010 | 3254 | 0.080 |
Why?
|
| Eyelids | 3 | 1997 | 163 | 0.080 |
Why?
|
| Conjunctivitis, Allergic | 1 | 1987 | 20 | 0.080 |
Why?
|
| Disease Progression | 2 | 2010 | 6682 | 0.080 |
Why?
|
| Vision, Binocular | 1 | 2008 | 71 | 0.080 |
Why?
|
| Cyanoacrylates | 1 | 1987 | 41 | 0.080 |
Why?
|
| Microscopy | 1 | 2009 | 182 | 0.080 |
Why?
|
| Connective Tissue Diseases | 1 | 1987 | 50 | 0.080 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2007 | 44 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 502 | 0.080 |
Why?
|
| Leukocytes | 1 | 2009 | 422 | 0.080 |
Why?
|
| Tissue Adhesives | 1 | 1987 | 51 | 0.080 |
Why?
|
| Atrophy | 1 | 2008 | 261 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2008 | 6009 | 0.080 |
Why?
|
| Conjunctivitis, Viral | 1 | 1987 | 1 | 0.080 |
Why?
|
| Fluorescent Dyes | 2 | 1986 | 459 | 0.070 |
Why?
|
| Kinetics | 2 | 2009 | 2049 | 0.070 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2007 | 176 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 4320 | 0.070 |
Why?
|
| Tissue Culture Techniques | 1 | 2007 | 114 | 0.070 |
Why?
|
| United States | 8 | 2008 | 15433 | 0.070 |
Why?
|
| Disease Transmission, Infectious | 1 | 2008 | 94 | 0.070 |
Why?
|
| Cellulitis | 3 | 1996 | 72 | 0.070 |
Why?
|
| Conjunctivitis, Inclusion | 1 | 1986 | 2 | 0.070 |
Why?
|
| Adenovirus Infections, Human | 1 | 1987 | 56 | 0.070 |
Why?
|
| Maxillary Diseases | 1 | 1986 | 3 | 0.070 |
Why?
|
| Bibliometrics | 1 | 2007 | 71 | 0.070 |
Why?
|
| Antigens, Bacterial | 1 | 1989 | 354 | 0.070 |
Why?
|
| Myiasis | 1 | 1986 | 4 | 0.070 |
Why?
|
| Epithelium | 4 | 1996 | 720 | 0.070 |
Why?
|
| Medical History Taking | 1 | 2007 | 173 | 0.070 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2014 | 314 | 0.070 |
Why?
|
| Antibodies | 1 | 2009 | 838 | 0.070 |
Why?
|
| Herpes Zoster Ophthalmicus | 4 | 1987 | 12 | 0.070 |
Why?
|
| Humidity | 1 | 2005 | 29 | 0.070 |
Why?
|
| Uveitis | 3 | 1987 | 33 | 0.070 |
Why?
|
| Brain Abscess | 1 | 1986 | 60 | 0.070 |
Why?
|
| Infectious Mononucleosis | 2 | 1986 | 33 | 0.070 |
Why?
|
| Cytophagaceae | 1 | 1985 | 1 | 0.070 |
Why?
|
| Interferon Type I | 1 | 1987 | 250 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2002 | 1391 | 0.070 |
Why?
|
| HIV | 1 | 1987 | 229 | 0.070 |
Why?
|
| Idoxuridine | 2 | 1982 | 17 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2009 | 677 | 0.070 |
Why?
|
| Horse Diseases | 1 | 1985 | 28 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2010 | 2074 | 0.060 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2004 | 24 | 0.060 |
Why?
|
| Muramidase | 1 | 1985 | 110 | 0.060 |
Why?
|
| False Positive Reactions | 2 | 2004 | 355 | 0.060 |
Why?
|
| Retinoscopy | 1 | 2004 | 10 | 0.060 |
Why?
|
| Medulla Oblongata | 1 | 2004 | 45 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 399 | 0.060 |
Why?
|
| Methylcellulose | 1 | 1984 | 9 | 0.060 |
Why?
|
| Antigens, Viral | 3 | 2000 | 471 | 0.060 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2006 | 129 | 0.060 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 1984 | 18 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 181 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2004 | 275 | 0.060 |
Why?
|
| Drug Evaluation | 2 | 2003 | 425 | 0.060 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 1985 | 108 | 0.060 |
Why?
|
| Incidence | 3 | 2007 | 5673 | 0.060 |
Why?
|
| Chemical Precipitation | 1 | 2003 | 23 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2009 | 1442 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2007 | 837 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2004 | 543 | 0.060 |
Why?
|
| Crystallization | 1 | 2003 | 132 | 0.060 |
Why?
|
| Diplopia | 1 | 2004 | 66 | 0.060 |
Why?
|
| Chronic Disease | 3 | 2002 | 1819 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6207 | 0.060 |
Why?
|
| Therapeutic Irrigation | 1 | 1983 | 90 | 0.060 |
Why?
|
| Refractive Errors | 1 | 2004 | 95 | 0.060 |
Why?
|
| RNA | 1 | 2008 | 1013 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 1986 | 236 | 0.060 |
Why?
|
| Range of Motion, Articular | 1 | 2004 | 144 | 0.060 |
Why?
|
| Scedosporium | 1 | 2003 | 23 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 1533 | 0.060 |
Why?
|
| Gentamicins | 2 | 2000 | 90 | 0.060 |
Why?
|
| Cause of Death | 3 | 2008 | 752 | 0.060 |
Why?
|
| Bacterial Typing Techniques | 1 | 2003 | 139 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1984 | 233 | 0.050 |
Why?
|
| Drainage | 2 | 1998 | 416 | 0.050 |
Why?
|
| Models, Economic | 1 | 2003 | 101 | 0.050 |
Why?
|
| Decision Trees | 1 | 2003 | 178 | 0.050 |
Why?
|
| Random Allocation | 4 | 1995 | 703 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2007 | 1021 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 4 | 1991 | 544 | 0.050 |
Why?
|
| Phenylephrine | 2 | 2004 | 48 | 0.050 |
Why?
|
| Aqueous Humor | 2 | 2001 | 29 | 0.050 |
Why?
|
| Dry Eye Syndromes | 1 | 2006 | 286 | 0.050 |
Why?
|
| Observer Variation | 1 | 2004 | 671 | 0.050 |
Why?
|
| Cell Movement | 1 | 2009 | 2466 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2003 | 700 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2003 | 409 | 0.050 |
Why?
|
| Animal Testing Alternatives | 1 | 2001 | 3 | 0.050 |
Why?
|
| Consumer Product Safety | 1 | 2001 | 26 | 0.050 |
Why?
|
| Glaucoma, Open-Angle | 2 | 1992 | 38 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2006 | 501 | 0.050 |
Why?
|
| Drug Costs | 1 | 2003 | 144 | 0.050 |
Why?
|
| Health Services Research | 1 | 2003 | 233 | 0.050 |
Why?
|
| Phenolsulfonphthalein | 1 | 2000 | 1 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2003 | 329 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2003 | 418 | 0.050 |
Why?
|
| Indicators and Reagents | 1 | 2000 | 128 | 0.050 |
Why?
|
| Linear Models | 1 | 2003 | 1085 | 0.050 |
Why?
|
| Cytokines | 1 | 2009 | 2809 | 0.050 |
Why?
|
| Bias | 1 | 2001 | 205 | 0.050 |
Why?
|
| Mental Recall | 1 | 2001 | 171 | 0.050 |
Why?
|
| Cefazolin | 1 | 2000 | 25 | 0.050 |
Why?
|
| Southeastern United States | 1 | 2000 | 54 | 0.050 |
Why?
|
| Prevalence | 1 | 2008 | 3260 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 3 | 1985 | 218 | 0.040 |
Why?
|
| Adhesins, Bacterial | 1 | 2000 | 85 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2009 | 5710 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2000 | 234 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2001 | 332 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2009 | 6150 | 0.040 |
Why?
|
| Lacrimal Apparatus | 2 | 2000 | 181 | 0.040 |
Why?
|
| Actinomycetales Infections | 1 | 1979 | 15 | 0.040 |
Why?
|
| Decision Making | 1 | 2007 | 1287 | 0.040 |
Why?
|
| Capsid Proteins | 1 | 2000 | 185 | 0.040 |
Why?
|
| Gram-Positive Bacteria | 2 | 1997 | 66 | 0.040 |
Why?
|
| Charcoal | 1 | 1998 | 8 | 0.040 |
Why?
|
| Agar | 1 | 1998 | 26 | 0.040 |
Why?
|
| Buffers | 1 | 1998 | 44 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 2 | 1998 | 418 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 2 | 2000 | 966 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2003 | 945 | 0.040 |
Why?
|
| Yeasts | 1 | 1998 | 74 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2001 | 574 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 6295 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 2000 | 224 | 0.040 |
Why?
|
| Triazoles | 1 | 2003 | 617 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2001 | 465 | 0.040 |
Why?
|
| Simplexvirus | 2 | 1991 | 159 | 0.040 |
Why?
|
| Mass Screening | 1 | 1987 | 1509 | 0.040 |
Why?
|
| Infant | 4 | 2004 | 13310 | 0.040 |
Why?
|
| Collagen | 2 | 2000 | 752 | 0.040 |
Why?
|
| Wound Healing | 2 | 2000 | 815 | 0.040 |
Why?
|
| Safety | 1 | 1999 | 465 | 0.040 |
Why?
|
| Penicillins | 1 | 1998 | 143 | 0.040 |
Why?
|
| Naphazoline | 1 | 1997 | 2 | 0.040 |
Why?
|
| Nasal Decongestants | 1 | 1997 | 4 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1998 | 148 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2004 | 1863 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2001 | 2403 | 0.040 |
Why?
|
| Young Adult | 1 | 2015 | 21445 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 1993 | 3472 | 0.040 |
Why?
|
| Age Factors | 2 | 2003 | 5377 | 0.040 |
Why?
|
| Fluorometholone | 1 | 1996 | 3 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 1991 | 1165 | 0.040 |
Why?
|
| Intraocular Pressure | 3 | 1982 | 146 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2002 | 1085 | 0.040 |
Why?
|
| Microscopy, Electron | 2 | 1994 | 600 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 1996 | 60 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2000 | 548 | 0.030 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1997 | 157 | 0.030 |
Why?
|
| Inflammation | 5 | 1988 | 2522 | 0.030 |
Why?
|
| Cyclodextrins | 1 | 1995 | 7 | 0.030 |
Why?
|
| Mitomycins | 1 | 1995 | 48 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2010 | 8223 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 1995 | 74 | 0.030 |
Why?
|
| Prognosis | 3 | 2007 | 21713 | 0.030 |
Why?
|
| Anesthetics, Local | 1 | 1996 | 163 | 0.030 |
Why?
|
| Acute Disease | 4 | 1998 | 2422 | 0.030 |
Why?
|
| Regression Analysis | 2 | 1994 | 1546 | 0.030 |
Why?
|
| Lacrimal Apparatus Diseases | 2 | 1986 | 137 | 0.030 |
Why?
|
| Fluorescein Angiography | 1 | 1995 | 139 | 0.030 |
Why?
|
| Internship and Residency | 1 | 1985 | 1375 | 0.030 |
Why?
|
| Injections | 2 | 2006 | 285 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2000 | 1029 | 0.030 |
Why?
|
| Cell Count | 2 | 1992 | 508 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1995 | 163 | 0.030 |
Why?
|
| Patient Compliance | 2 | 1994 | 667 | 0.030 |
Why?
|
| Blepharitis | 2 | 1997 | 8 | 0.030 |
Why?
|
| Drug Carriers | 1 | 1995 | 327 | 0.030 |
Why?
|
| Research Design | 2 | 1991 | 1544 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 1996 | 482 | 0.030 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 1992 | 16 | 0.030 |
Why?
|
| Mutation | 2 | 2010 | 15179 | 0.030 |
Why?
|
| Cyclosporins | 2 | 1982 | 112 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 1992 | 121 | 0.030 |
Why?
|
| Suture Techniques | 1 | 2014 | 319 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1994 | 1323 | 0.030 |
Why?
|
| Inclusion Bodies, Viral | 1 | 1991 | 13 | 0.030 |
Why?
|
| Immunoglobulin G | 3 | 2000 | 1021 | 0.030 |
Why?
|
| Staphylococcus | 1 | 1991 | 86 | 0.030 |
Why?
|
| Species Specificity | 2 | 2000 | 777 | 0.020 |
Why?
|
| Americas | 1 | 1991 | 52 | 0.020 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 1991 | 49 | 0.020 |
Why?
|
| Graft Survival | 1 | 1995 | 1062 | 0.020 |
Why?
|
| Betaxolol | 1 | 1990 | 2 | 0.020 |
Why?
|
| Levobunolol | 1 | 1990 | 2 | 0.020 |
Why?
|
| Imidazoles | 1 | 1997 | 999 | 0.020 |
Why?
|
| Africa | 1 | 1991 | 142 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2014 | 500 | 0.020 |
Why?
|
| Asia | 1 | 1991 | 142 | 0.020 |
Why?
|
| Tears | 3 | 1987 | 181 | 0.020 |
Why?
|
| Australia | 1 | 1991 | 225 | 0.020 |
Why?
|
| Necrosis | 2 | 1995 | 580 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2003 | 3518 | 0.020 |
Why?
|
| Chondroitin | 1 | 1989 | 5 | 0.020 |
Why?
|
| HEPES | 1 | 1989 | 2 | 0.020 |
Why?
|
| Placebos | 1 | 1991 | 437 | 0.020 |
Why?
|
| Chondroitin Sulfates | 1 | 1989 | 21 | 0.020 |
Why?
|
| Keratotomy, Radial | 1 | 1989 | 26 | 0.020 |
Why?
|
| Natamycin | 1 | 2009 | 2 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1996 | 1682 | 0.020 |
Why?
|
| Descemet Membrane | 1 | 1989 | 10 | 0.020 |
Why?
|
| Europe | 1 | 1991 | 649 | 0.020 |
Why?
|
| Saline Solution, Hypertonic | 1 | 1989 | 26 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 1995 | 2843 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1991 | 467 | 0.020 |
Why?
|
| Eye Neoplasms | 1 | 1991 | 247 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 7702 | 0.020 |
Why?
|
| Program Evaluation | 1 | 1991 | 597 | 0.020 |
Why?
|
| Penicillin G Benzathine | 1 | 1987 | 16 | 0.020 |
Why?
|
| Vidarabine | 2 | 2004 | 1341 | 0.020 |
Why?
|
| Ear Diseases | 1 | 1987 | 21 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1996 | 4938 | 0.020 |
Why?
|
| Neuromuscular Junction | 1 | 1987 | 90 | 0.020 |
Why?
|
| Biopsy | 1 | 1995 | 3443 | 0.020 |
Why?
|
| Citrobacter | 1 | 1986 | 22 | 0.020 |
Why?
|
| Chlamydia trachomatis | 1 | 1986 | 30 | 0.020 |
Why?
|
| Cefuroxime | 1 | 2006 | 15 | 0.020 |
Why?
|
| Fluorophotometry | 1 | 2006 | 34 | 0.020 |
Why?
|
| Ofloxacin | 1 | 2006 | 41 | 0.020 |
Why?
|
| Inclusion Bodies | 1 | 1986 | 76 | 0.020 |
Why?
|
| Levofloxacin | 1 | 2006 | 57 | 0.020 |
Why?
|
| Anterior Chamber | 1 | 2006 | 51 | 0.020 |
Why?
|
| Contact Lenses, Extended-Wear | 1 | 1985 | 5 | 0.020 |
Why?
|
| HIV Seropositivity | 1 | 1987 | 144 | 0.020 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1986 | 69 | 0.020 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 1986 | 53 | 0.020 |
Why?
|
| Plasma Cells | 1 | 1986 | 192 | 0.020 |
Why?
|
| Clindamycin | 1 | 1985 | 50 | 0.020 |
Why?
|
| Penicillin G | 2 | 1984 | 10 | 0.020 |
Why?
|
| Horses | 1 | 1985 | 96 | 0.020 |
Why?
|
| Enterobacter | 1 | 1984 | 20 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 1986 | 220 | 0.020 |
Why?
|
| Drug Packaging | 1 | 1984 | 13 | 0.020 |
Why?
|
| Lung | 1 | 1996 | 3151 | 0.020 |
Why?
|
| Cyclopentolate | 1 | 2004 | 8 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1986 | 684 | 0.020 |
Why?
|
| Tropicamide | 1 | 2004 | 8 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 1984 | 61 | 0.020 |
Why?
|
| Mydriatics | 1 | 2004 | 26 | 0.020 |
Why?
|
| Health Status | 1 | 2008 | 590 | 0.020 |
Why?
|
| Amblyopia | 1 | 2004 | 112 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2008 | 627 | 0.020 |
Why?
|
| Electroretinography | 1 | 1984 | 116 | 0.010 |
Why?
|
| Image Enhancement | 1 | 1988 | 561 | 0.010 |
Why?
|
| Aspergillus | 1 | 1985 | 149 | 0.010 |
Why?
|
| Pupil | 1 | 2004 | 54 | 0.010 |
Why?
|
| Herpesvirus 1, Human | 1 | 2004 | 113 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1986 | 295 | 0.010 |
Why?
|
| Mycetoma | 1 | 2003 | 10 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1986 | 402 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1984 | 573 | 0.010 |
Why?
|
| Texas | 1 | 1994 | 6311 | 0.010 |
Why?
|
| Voriconazole | 1 | 2003 | 108 | 0.010 |
Why?
|
| Epithelium, Corneal | 1 | 2004 | 223 | 0.010 |
Why?
|
| Clobetasol | 1 | 1981 | 9 | 0.010 |
Why?
|
| Choroiditis | 1 | 1981 | 1 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1987 | 691 | 0.010 |
Why?
|
| Neutrophils | 1 | 1986 | 835 | 0.010 |
Why?
|
| Neisseriaceae | 1 | 1980 | 1 | 0.010 |
Why?
|
| Florida | 1 | 2001 | 113 | 0.010 |
Why?
|
| Streptococcal Infections | 1 | 1984 | 280 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1986 | 1234 | 0.010 |
Why?
|
| Lenses, Intraocular | 1 | 1985 | 346 | 0.010 |
Why?
|
| Models, Anatomic | 1 | 2001 | 154 | 0.010 |
Why?
|
| Cephalexin | 1 | 2000 | 7 | 0.010 |
Why?
|
| Piperazines | 1 | 1989 | 2101 | 0.010 |
Why?
|
| Steroids | 1 | 1982 | 356 | 0.010 |
Why?
|
| Self Concept | 1 | 2001 | 211 | 0.010 |
Why?
|
| Capsid | 1 | 2000 | 103 | 0.010 |
Why?
|
| Social Behavior | 1 | 2001 | 306 | 0.010 |
Why?
|
| Bacterial Adhesion | 1 | 2000 | 147 | 0.010 |
Why?
|
| Actinomycetales | 1 | 1979 | 3 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 2006 | 927 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2000 | 347 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2000 | 7551 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2000 | 435 | 0.010 |
Why?
|
| Nonprescription Drugs | 1 | 1997 | 52 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 1997 | 104 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1981 | 1450 | 0.010 |
Why?
|
| Propoxycaine | 1 | 1996 | 2 | 0.010 |
Why?
|
| Procaine | 1 | 1996 | 8 | 0.010 |
Why?
|
| Biological Availability | 2 | 1987 | 214 | 0.010 |
Why?
|
| Tetracaine | 1 | 1996 | 9 | 0.010 |
Why?
|
| Self Medication | 1 | 1996 | 23 | 0.010 |
Why?
|
| Serotyping | 1 | 1994 | 166 | 0.010 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1995 | 129 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 1981 | 1547 | 0.010 |
Why?
|
| Disposable Equipment | 1 | 1993 | 18 | 0.010 |
Why?
|
| Protein Binding | 1 | 2000 | 3438 | 0.010 |
Why?
|
| Neuralgia | 2 | 1987 | 251 | 0.010 |
Why?
|
| Patient Participation | 1 | 1996 | 446 | 0.010 |
Why?
|
| Beta Particles | 1 | 1991 | 13 | 0.010 |
Why?
|
| Strontium Radioisotopes | 1 | 1991 | 26 | 0.010 |
Why?
|
| Fixatives | 1 | 1989 | 28 | 0.010 |
Why?
|
| Tissue Preservation | 1 | 1989 | 30 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2001 | 5687 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1989 | 220 | 0.010 |
Why?
|
| Conjunctival Neoplasms | 1 | 1991 | 120 | 0.010 |
Why?
|
| Cryosurgery | 1 | 1991 | 167 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1991 | 1618 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 410 | 0.000 |
Why?
|
| Sensation | 1 | 1987 | 71 | 0.000 |
Why?
|
| Parotid Gland | 1 | 1986 | 112 | 0.000 |
Why?
|
| Salivary Glands | 1 | 1986 | 130 | 0.000 |
Why?
|
| Serologic Tests | 1 | 1986 | 137 | 0.000 |
Why?
|
| Organic Chemicals | 1 | 1986 | 113 | 0.000 |
Why?
|
| Herpesvirus 3, Human | 1 | 1985 | 43 | 0.000 |
Why?
|
| Microscopy, Fluorescence | 1 | 1986 | 769 | 0.000 |
Why?
|
| Autoantibodies | 1 | 1986 | 576 | 0.000 |
Why?
|
| Skin Diseases | 1 | 1985 | 349 | 0.000 |
Why?
|
| Epithelial Cells | 1 | 1989 | 1818 | 0.000 |
Why?
|
| Depression, Chemical | 1 | 1981 | 52 | 0.000 |
Why?
|
| Skin | 1 | 1986 | 1259 | 0.000 |
Why?
|
| Rats | 1 | 1987 | 6086 | 0.000 |
Why?
|
| Pain | 1 | 1986 | 1658 | 0.000 |
Why?
|